Zymeworks presents new ZW1528 data at ATS conference

Zymeworks (ZYME) announced the presentation of new preclinical data for ZW1528, a novel IL-4Ra x IL-33 bispecific molecule designed to address respiratory inflammation, at the American Thoracic Society International Conference being held May 18-21 in San Francisco, California. Key findings for ZW1528 include: high-affinity binding to both IL-33 and IL-4Ra and effective blockade of IL-4, IL-13, and IL-33 signaling at levels comparable to clinical benchmark monoclonal antibody controls. Suppression of both Type 2 and non-Type 2 responses in primary human immune cells of COPD patients in vitro. Efficacy in vivo in acute and chronic murine models of lung inflammation driven by house dust mites. Extended pharmacokinetics in rodent and non-human primate models, with incorporation of Fc extending half-life optimization. Biophysical stability at high concentration, supporting potential for subcutaneous administration.